Navigation Links
Vion Pharmaceuticals to Present at 20th Annual Bear Stearns Healthcare Conference
Date:9/10/2007

NEW HAVEN, Conn., Sept. 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced today that it would make a corporate presentation at the 20th annual Bear Stearns Healthcare Conference on Tuesday, September 11, 2007 at 4:30 p.m. Eastern Time. The conference is taking place at the Grand Hyatt Hotel in New York City and the presentation will be in Ballroom D (Morosco).

Slides from the presentation will be posted to Vion's website, http://www.vionpharm.com, at 4:30 p.m. Eastern Time on September 11, 2007.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

Th
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... April 24, 2008 / b3c newswire / - ... are working on a project to synthesize a gene ... statistically expected and controlled ratio at preselected positions within ... core technology, Slonomics™, a unique DNA engineering platform using ...
... N.C. -- Duke University chemists have found a way ... thick in very large numbers, removing a major roadblock ... These single-walled carbon nanotubes also follow parallel paths as ... potentially impede electronic performance, said Duke associate chemistry professor ...
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced ... results on Wednesday, April 30,2008, after the market closes. ... at 2:00 p.m. PT, which will be open to ... the company will review,the financial results and discuss other ...
Cached Biology Technology:Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library 2Nanotubes grown straight in large numbers 2Nanotubes grown straight in large numbers 3Sangamo BioSciences Announces First Quarter Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter Conference Call and Webcast 3
(Date:4/22/2014)... Analyzing thousands of breeding bird surveys sent in ... Canada over 35 years, wildlife researchers report that most ... northward or toward higher elevation in response to climate ... means that most previous studies of potential climate change ... or the other have likely underestimated the effects of ...
(Date:4/22/2014)... effects of temperature and precipitation on the global distribution ... of climate research, the UV-B radiation, is often neglected. ... colleagues from the Universities in Olomouc (Czechia), Halle and ... space agency in such a way that they can ... on organisms. , The basic input data were provided ...
(Date:4/22/2014)... your age" is another way of asking him or ... bring improvements. Certain cells of the immune system tend ... to illness. Because these cells are known to misbehave ... microgravity on immune cells to better understand how our ... the National Institute on Aging, part of the National ...
Breaking Biology News(10 mins):Wildlife response to climate change is likely underestimated, experts warn 2UV-radiation data to help ecological research 2For an immune cell, microgravity mimics aging 2For an immune cell, microgravity mimics aging 3For an immune cell, microgravity mimics aging 4For an immune cell, microgravity mimics aging 5
... , WEST LAFAYETTE, Ind. - Scientists could take greater ... of advanced techniques used to understand the mechanisms that ... former Purdue University researchers say. In a perspective ... Purdue assistant professor of genetics, and Ivan Baxter, a ...
... could make more tomatoes taste like heirlooms, reports an international ... scientist. The finding, which will be reported in the ... significant implications for the U.S. tomato industry, which annually harvests ... and fresh-market sales. "This information about the gene responsible ...
... big boss proteins that switch on broad developmental ... regulators of muscle development or fat metabolism. One ... protein, takes charge following a cellular crisis known ... by the accumulation of misfolded and aggregated proteins. ...
Cached Biology News:Adoption of advanced techniques could propel crop improvement 2Discovery may lead to new tomato varieties with vintage flavor and quality 2Forty's a crowd 2Forty's a crowd 3Forty's a crowd 4
Immunochemistry 1 & 2...
...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Biology Products: